Literature DB >> 30023400

Revolutionary changes in salvage treatment for Hodgkin lymphoma: toward a chemotherapy-free future.

Jiawen Chen1, Wei Yang1, Zimu Gong1,2,3.   

Abstract

Entities:  

Year:  2018        PMID： 30023400      PMCID： PMC6035995          DOI： 10.21037/atm.2018.05.39

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  10 in total

1.  Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

Authors:  A Martín; M C Fernández-Jiménez; M D Caballero; M A Canales; J A Pérez-Simón; J García de Bustos; L Vázquez; F Hernández-Navarro; J F San Miguel
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

2.  Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

Authors:  A Sureda; R Arranz; A Iriondo; E Carreras; J J Lahuerta; J García-Conde; I Jarque; M D Caballero; C Ferrà; A López; J García-Laraña; R Cabrera; D Carrera; M D Ruiz-Romero; A León; J Rifón; J Díaz-Mediavilla; R Mataix; M Morey; J M Moraleda; A Altés; A López-Guillermo; J de la Serna; J M Fernández-Rañada; J Sierra; E Conde
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Authors:  Chun-Meng Wang; Zhi-Qiang Wu; Yao Wang; Ye-Lei Guo; Han-Ren Dai; Xiao-Hui Wang; Xiang Li; Ya-Jing Zhang; Wen-Ying Zhang; Mei-Xia Chen; Yan Zhang; Kai-Chao Feng; Yang Liu; Su-Xia Li; Qing-Ming Yang; Wei-Dong Han
Journal:  Clin Cancer Res       Date:  2016-08-31       Impact factor: 12.531

4.  Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Authors:  Dennis A Eichenauer; Annette Plütschow; Stefanie Kreissl; Martin Sökler; Johannes C Hellmuth; Julia Meissner; Stephan Mathas; Max S Topp; Karolin Behringer; Wolfram Klapper; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Michael Fuchs; Volker Diehl; Andreas Engert; Peter Borchmann
Journal:  Lancet Oncol       Date:  2017-11-10       Impact factor: 41.316

5.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

6.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

7.  Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Authors:  Anas Younes; Joseph M Connors; Steven I Park; Michelle Fanale; Megan M O'Meara; Naomi N Hunder; Dirk Huebner; Stephen M Ansell
Journal:  Lancet Oncol       Date:  2013-11-15       Impact factor: 41.316

8.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Authors:  Catherine M Bollard; Stephen Gottschalk; Vicky Torrano; Oumar Diouf; Stephanie Ku; Yasmin Hazrat; George Carrum; Carlos Ramos; Luis Fayad; Elizabeth J Shpall; Barbara Pro; Hao Liu; Meng-Fen Wu; Daniel Lee; Andrea M Sheehan; Youli Zu; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

9.  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Alex F Herrera; Alison J Moskowitz; Nancy L Bartlett; Julie M Vose; Radhakrishnan Ramchandren; Tatyana A Feldman; Ann S LaCasce; Stephen M Ansell; Craig H Moskowitz; Keenan Fenton; Carol Anne Ogden; David Taft; Qu Zhang; Kazunobu Kato; Mary Campbell; Ranjana H Advani
Journal:  Blood       Date:  2017-12-11       Impact factor: 25.476

10.  Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

Authors:  Owen A O'Connor; Jennifer K Lue; Ahmed Sawas; Jennifer E Amengual; Changchun Deng; Matko Kalac; Lorenzo Falchi; Enrica Marchi; Ithamar Turenne; Renee Lichtenstein; Celeste Rojas; Mark Francescone; Lawrence Schwartz; Bin Cheng; Kerry J Savage; Diego Villa; Michael Crump; Anca Prica; Vishal Kukreti; Serge Cremers; Joseph M Connors; John Kuruvilla
Journal:  Lancet Oncol       Date:  2017-12-21       Impact factor: 54.433
  10 in total
  1 in total

1.  SUMO1 modification of histone H4 is involved in the pathogenesis of nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  Hongyu Li; Li Guo; Bingyu Li; Xun Li
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.